Introduction: Breast cancer in young women
INTRODUCTION
Approximately, 5% of invasive breast cancers occur in women under the age of 40 years [1] and breast cancer is the leading cause of cancer-related deaths in women between the ages of 20-39 years [2] . Overall survival (OS) rates are lower compared with those of older women [3] [4] [5] .
Young age is often delineated as premenopausal (approximately\50 years) [6] , but much of the literature defines young age as \35 or \40 years. Reports have attributed worsening prognosis of young women to biological factors, including lower estrogen receptor/progesterone receptor (ER/PR) expression [7, 8] or overexpression of human epidermal growth factor receptor 2 (HER2) [9] ; higher incidence of triple-negative disease (TNBC; absence of PR, ER, and HER2) [10] ; vascular invasion [7] ; nodal status [8] ; and higher grade [5, 7] . Other reports found that age conferred a worse prognosis, irrespective of pathologic features [7] , delay in diagnosis [11] , or higher treatment intensity, particularly in women aged \35 years [12] . Therefore, young age is frequently used as an indication for recommendation of adjuvant chemotherapy. guidelines for treatment decisions [13] [14] [15] [16] [17] , based on both the prognostic and predictive information the score provides. Decisions guided by the Recurrence Score result can spare women the toxic effects of chemotherapy, such as cardiotoxicity, secondary cancers, and neurotoxicity [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] , based on the prediction of little to no benefit in patients with a low score, as well as identifying women with high risk of recurrence who are likely to benefit meaningfully from chemotherapy.
Overall, there are limited data regarding age-specific biological differences and response to therapy in young women with ER? disease.
The objective of the analyses in this paper was to determine if the Recurrence Score result provided clinically meaningful differences in predicted risk of recurrence in younger compared with older patients.
METHODS
All ER? [ER by reverse transcriptase-polymerase chain reaction (RT-PCR) C6.5 threshold cycle] tumor specimens that were successfully examined in the Genomic Health (GHI) central reference laboratory (as per methods previously described) [28] from June 1, 2004 through December 31, 2013 were included in these analyses. The 21-gene assay was performed according to methods previously described [29] .
Statistical Analysis
Clinical data routinely submitted to GHI on the 
RESULTS

Demographics and Characteristics of Patients
The analysis included samples with successful Recurrence Score results from 394,031 patients in the GHI database (Table 1 ). More than 99% of patients were aged 25-90 years. The majority (81%) were aged 40-69 years; 3.3% (n = 13,029)
were \40 years, and 15.6% (n = 61,643) were C70 years (Fig. 1) . The most common histology was invasive ductal [not otherwise specified (NOS)] in 81.6% of patients. Nodal status was specified for 362,001 patients, and 87.0% (n = 314,875) were node-negative (Fig. 2) .
The age spread among the patients in the GHI database (N = 394,031) was also compared to the age spread among patients with newly diagnosed breast cancer in the American Cancer Society (ACS) database (N = 232,340) [1] .
Within the GHI and ACS databases, there were a similar proportion of patients aged \40 (3.3% and 4.7%), \50 (23.0% and 21.1%), and C50 (77.0% and 78.9%) years, respectively.
Distribution of Recurrence Score Risk Groups
A wide range of Recurrence Score results and risk stratification was observed within all age groups (Figs. 3, 4) . Overall, 58.5% (n = 230,529), 33.0% (n = 130,082), and 8.5% (n = 33,420) of patients had a low (\18), intermediate (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , or high (C31) Recurrence Score result, respectively. The proportion of low-and high-risk scores was comparable across the age groups. Notably, a greater proportion of patients aged \40 years appear to have high Recurrence Score results compared with patients aged C70 years (14.1% vs. 8.8%), and the median score was slightly higher in patients \40 years (18) and slightly lower in all other age groups (medians for 40-49, 50-59, 60-69, and C70-year groups were: 16, 17, 16, and 16, respectively).
Histologic Subtypes and Distribution of Recurrence Score Risk Groups by Age
Ductal carcinoma NOS accounted for 81.6% of the histologic type overall and 78-85% across the age groups with the highest proportion in the \40-year group (84.7%) and the lowest proportion in the C70-year group (78.1%; Fig. 1 
Comparison of Quantitative Gene Expression by Age and Recurrence Score Result
A wide range of quantitative ER and PR gene expression, as well as the proliferation index and invasion index, was observed within all age groups. ER expression increased with increasing age with a median of 9.3 in the \40-year group and 10.6 in the C70-year group. There was a slight decrease in PR expression across age categories with medians of 7.8 and 7.5, respectively. The maximum observed ER values represented more than a 100-fold greater RNA expression than the cutpoint for positivity of 6.5 in all age groups. Expression of the proliferation index and invasion index was also similar across all age groups (Fig. 6 ). An analysis of the ER and PR co-expression by age group and Recurrence Score risk group is shown in Fig. 7 . Across all risk groups there was a consistent pattern of increasing median ER and decreasing median PR with increasing age. Increases in median ER were most pronounced in low-risk patients (9.5 in patients aged \40
years to 11.0 in patients aged C70 years), although all median ER values were substantially above the threshold for positivity (6.5) . Decreasing median PR expression as a function of age was most pronounced in the high-risk group (6.0 in patients aged \40 years to 4.5 in patients aged C70 years). 
DISCUSSION
The 21-gene Recurrence Score result is widely used in the United States to guide the addition of adjuvant chemotherapy to endocrine therapy [30] [31] [32] . While the overall treatment paradigm has shifted substantially as a result, there continues to be a more conservative approach for treatment recommendations in younger women. As age has been traditionally associated with a poorer prognosis, young women are more often offered chemotherapy, irrespective of their Recurrence Score result. Two of the studies validating the Recurrence Score result included a lower proportion (8.8-9 .7%) of younger women [26, 33] .
However, these studies and others have consistently shown that the Recurrence Score result provides prognostic and predictive information independent of age and that there is a broad range of scores across age categories [34] [35] [36] [37] .
The GHI clinical laboratory has now processed more than 394,000 samples over a Recurrence Score results across the age categories was consistent with the overall cohort except for the \40-year group which had a lower proportion of patients with low-risk scores (48.2%) and a greater proportion of high-risk scores (14.1%). Of note, the 40-to 49-year group had the highest proportion of low-risk scores (60.1%) and the smallest proportion of high-risk scores (7.4%). In addition, there were small differences in the median Recurrence Score results between women aged \40 years and those aged C70 years (the higher median score of 18 was in patients aged \40 years), and the Recurrence Score result tended to decrease with advancing age. Similar observations were made when examining PR, proliferation index, and invasion index, with small absolute differences when data were stratified by age. ER values showed a larger increase as a function of age.
Other prognostic factors in addition to young age are also often used to determine course of treatment. These include histology, nodal status and older age (C70 years). Numerous studies have shown that young age at diagnosis is associated with poor outcome. and nodal status), leading to the conclusion that treatment should be driven by subtype biology and less influenced by age [40] . Our large series shows that the Recurrence Score result and the expression of invasion and proliferation genes have a similar distribution [41] . In this study, older patients and patients with small tumors were more likely to have a low Recurrence Score result, but the distribution of scores was not Patients with four or more nodes involved with a low score had a better outcome than patients with lower nodal burden but a high score. In addition to its prognostic information, the Recurrence Score result has also been shown to predict the benefit of adding adjuvant chemotherapy to endocrine therapy in a post-menopausal N? population. In the SWOG S8814 trial, which looked at the addition of chemotherapy to tamoxifen in post-menopausal, N? patients, the Recurrence Score result was a strong predictive factor of benefit from chemotherapy for disease-free survival [42] . Fig. 7 Quantitative ER and PR expression within age and Recurrence Score risk groups. Joint analysis of ER and PR expression within age and Recurrence Score risk groups shows that a wide and overlapping range of ER and PR expression is observed within age and risk groups. As with the population as a whole, there is generally an increase in median ER and a decrease in median PR with increasing age. The decrease in PR is most pronounced in high-risk patients. ER estrogen receptor, PR progesterone receptor, RT-PCR reverse transcriptase-polymerase chain reaction Limitations of our analysis include the absence of treatment information, other clinicopathologic characteristics (e.g., size and grade) and importantly, clinical outcomes.
However, the consistency in the proportion of patients within each Recurrence Score risk group across the age groups as well as within nodal status and histologic subtypes is consistent with the results from the validation subgroup analysis of NSABP B-14, in which the Recurrence Score result was shown to be prognostic over all age groups [29] . Since we did see a slightly greater proportion of high scores in the younger age group, there is a possibility that breast cancer in young women is enriched with more aggressive subtypes. 
